AriBioLab Co.,Ltd. (KOSDAQ:261780)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,595.00
+130.00 (5.27%)
At close: Sep 3, 2026

AriBioLab Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
173.16158.62370.66294.12179.48500
Revenue Growth
9.17%-57.21%26.02%63.87%-64.10%542.70%
Gross Profit
160.16143.92346.73259.62160.49500
Operating Income
-12,973-14,271-7,696-6,419-6,469-6,085
Net Income
-14,420-16,044-10,138-1,749-6,715-18,420
Earnings Per Share
-536.24-597.44-378.00-66.00-254.00-790.00
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
15,64123,67240,10738,89657,76361,550
Total Debt
6,1898,8419,5894,32723,63820,846
Net Cash (Debt)
9,45214,83130,51834,56934,12540,704
Net Cash Growth
-59.36%-51.40%-11.72%1.30%-16.16%579.94%
Net Cash Per Share
351.51552.251137.841304.131290.781745.71

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-9,173-11,017-8,096-5,293-5,189-4,740
Capital Expenditures
-31.74-116.84-179.21-278.58-447.4-679.57
Free Cash Flow
-9,205-11,134-8,275-5,572-5,636-5,419
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
92.49%90.73%93.55%88.27%89.42%100.00%
Operating Margin
-7491.67%-8997.23%-2076.42%-2182.53%-3604.36%-1216.93%
Pretax Margin
-8327.31%-10115.30%-2809.56%-715.10%-3741.36%-3684.01%
Profit Margin
-8327.31%-10115.30%-2735.23%-594.82%-3741.36%-3684.01%
FCF Margin
-5315.64%-7019.41%-2232.46%-1894.38%-3140.08%-1083.83%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
426.29478.48221.45513.51734.04586.73